Table 1.
Clinical parameters of study patients.
| Variables | IT (n = 15) | IA (n = 17) | AT (n = 13) | P-valuea (IT vs. AT) |
|---|---|---|---|---|
| Age (years), median (range) | 37 (25–53) | 42 (25–67) | 47 (25–74) | 0.005 |
| Male sex, n (%) | 8 (53) | 11 (65) | 8 (62) | |
| HBeAg/HBeAb | ||||
| +/– | 15 (100) | 11 (65) | 1 (8) | |
| +/+ | 0 (0) | 0 (0) | 0 (0) | |
| –/+ | 0 (0) | 6 (35) | 9 (69) | |
| Median HBV DNA level (log copies/mL) | 9.09 | 8.59 | 2.01 | <0.001 |
| ALT (U/L), median (range) | 34 (14–38) | 189 (52–1,599) | 25 (15–43) | 0.016 |
| Antiviral therapy, n (%) | ||||
| None | 15 (100) | 17 (100) | 0 (0) | |
| Adefovir | 0 (0) | 0 (0) | 1 (8) | |
| Entecavir | 0 (0) | 0 (0) | 8 (62) | |
| Tenofovir | 0 (0) | 0 (0) | 4 (30) |
ALT, Alanine aminotransferase; AT, antiviral treatment; HBeAb, hepatitis B envelope antibody; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IA, immune-active; IT, immune-tolerant.
a
P-value estimated by Mann-Whitney U-test or Kruskal-Wallis test.